Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations
- van Berlo – van de Laar, I. R.F.
- Brummelhuis, W. J.
- Imholz, A. L.T.
- Schellens, J. H.
- Huitema, A. D.R.
- Jansman, F. G.A.
DOIAbstract
What is known and objective: Oxaliplatin in combination with fluorouracil and folinic acid is one of the preferred chemotherapeutic options in the treatment of metastatic rectum cancer. However, oxaliplatin is contraindicated in patients with a creatinine clearance <30 mL/min and dosing guidelines in patients on haemodialysis have not been established. Case summary: A 77-year-old haemodialysis patient with metastatic rectum cancer was treated with FOLFOX and bevacizumab (oxaliplatin 70 mg/m2, folinic acid 200 mg/m2, 5-FU 340 mg/m2 bolus and 2040 mg/m2 continuous infusion during 44 hours and bevacizumab 5 mg/kg) every three weeks. Haemodialysis started immediately after infusion of oxaliplatin. The oxaliplatin dose was monitored by measuring...
Add to ORKG